Lys561
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus®
Powered by Cell Signaling Technology
Home > Ubiquitylation Site Page: > Lys561  -  FANCD2 (human)

Site Information
DMHLVIRkQLSSTVF   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 486248

In vivo Characterization
Methods used to characterize site in vivo:
mass spectrometry ( 1 , 6 , 8 , 9 , 10 , 12 , 13 , 14 , 15 , 16 , 17 , 18 , 19 , 20 , 21 , 22 , 23 , 24 , 25 , 26 , 27 , 28 , 29 , 30 , 31 , 32 , 33 , 34 , 35 , 36 , 37 , 38 , 39 , 40 , 41 , 42 , 43 , 44 , 45 , 46 , 47 , 48 , 49 , 50 , 51 , 52 , 53 , 54 , 55 , 56 , 57 , 58 , 59 , 60 , 61 , 62 , 63 , 64 )
Disease tissue studied:
leukemia ( 22 , 23 , 24 , 25 , 26 , 30 ) , acute lymphocytic leukemia ( 22 , 23 , 24 ) , chronic myelogenous leukemia ( 25 , 30 ) , T cell leukemia ( 26 ) , lung cancer ( 6 ) , non-small cell lung adenocarcinoma ( 6 ) , multiple myeloma ( 16 , 17 , 18 , 21 , 41 )
Relevant cell line - cell type - tissue:
293T (epithelial) ( 13 ) , A549 (pulmonary) ( 6 ) , DND-41 (T lymphocyte) ( 22 ) , HeLa (cervical) ( 31 ) , HEp-2 (squamous) ( 1 ) , JJN3 (plasma cell) ( 21 , 44 , 45 , 46 , 48 ) , Jurkat (T lymphocyte) ( 1 , 8 , 9 , 15 , 19 , 20 , 26 , 29 ) , K562 (erythroid) ( 25 , 30 ) , KMS-12-BM (B lymphocyte) ( 41 ) , KMS-27 (B lymphocyte) ( 37 , 43 ) , L-363 (plasma cell) ( 16 ) , LNCaP (prostate cell) ( 63 , 64 ) , MV4-11 (macrophage) ( 13 ) , NCCIT (epithelial) ( 27 ) , NT2 (testicular) ( 28 ) , PC3 (prostate cell) ( 57 , 58 , 59 , 60 , 61 ) , PD20 ( 62 ) , Reh (B lymphocyte) ( 23 ) , RPMI-8226 (plasma cell) ( 17 , 18 , 34 , 35 , 36 , 42 ) , SEM (B lymphocyte) ( 24 ) , U266 (plasma cell) ( 47 , 49 , 50 ) , U2OS (bone cell) ( 10 ) , U2OS (bone cell) [ubiquitin (human), transfection] ( 14 )

Upstream Regulation
Treatments:
MG132 ( 13 ) , vorinostat ( 6 )

References 

1

Akimov V, et al. (2018) UbiSite approach for comprehensive mapping of lysine and N-terminal ubiquitination sites. Nat Struct Mol Biol 25, 631-640
29967540   Curated Info

2

Lumpkin RJ, et al. (2017) Site-specific identification and quantitation of endogenous SUMO modifications under native conditions. Nat Commun 8, 1171
29079793   Curated Info

3

Hashimoto K, et al. (2016) Poor recognition of O6-isopropyl dG by MGMT triggers double strand break-mediated cell death and micronucleus induction in FANC-deficient cells. Oncotarget 7, 59795-59808
27486975   Curated Info

4

Kais Z, et al. (2016) FANCD2 Maintains Fork Stability in BRCA1/2-Deficient Tumors and Promotes Alternative End-Joining DNA Repair. Cell Rep 15, 2488-99
27264184   Curated Info

5

Boeing S, et al. (2016) Multiomic Analysis of the UV-Induced DNA Damage Response. Cell Rep 15, 1597-1610
27184836   Curated Info

6

Wu Q, et al. (2015) Suberoylanilide hydroxamic acid treatment reveals crosstalks among proteome, ubiquitylome and acetylome in non-small cell lung cancer A549 cell line. Sci Rep 5, 9520
25825284   Curated Info

7

Panneerselvam J, et al. (2013) A hidden role of the inactivated FANCD2: upregulating ΔNp63. Oncotarget 4, 1416-26
23965832   Curated Info

8

Mertins P, et al. (2013) Integrated proteomic analysis of post-translational modifications by serial enrichment. Nat Methods 10, 634-7
23749302   Curated Info

9

Udeshi ND, et al. (2013) Refined preparation and use of anti-diglycine remnant (K-ε-GG) antibody enables routine quantification of 10,000s of ubiquitination sites in single proteomics experiments. Mol Cell Proteomics 12, 825-31
23266961   Curated Info

10

Povlsen LK, et al. (2012) Systems-wide analysis of ubiquitylation dynamics reveals a key role for PAF15 ubiquitylation in DNA-damage bypass. Nat Cell Biol 14, 1089-98
23000965   Curated Info

11

Rego MA, et al. (2012) Regulation of the Fanconi anemia pathway by a CUE ubiquitin-binding domain in the FANCD2 protein. Blood 120, 2109-17
22855611   Curated Info

12

Kim W, et al. (2011) Systematic and quantitative assessment of the ubiquitin-modified proteome. Mol Cell 44, 325-40
21906983   Curated Info

13

Wagner SA, et al. (2011) A Proteome-wide, Quantitative Survey of In Vivo Ubiquitylation Sites Reveals Widespread Regulatory Roles. Mol Cell Proteomics 10, M111.013284
21890473   Curated Info

14

Danielsen JM, et al. (2011) Mass spectrometric analysis of lysine ubiquitylation reveals promiscuity at site level. Mol Cell Proteomics 10, M110.003590
21139048   Curated Info

15

Possemato A (2010) CST Curation Set: 10533; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: Ub(K-e-GG) Antibodies Used to Purify Peptides prior to LCMS: Ubiquitin (D4A7A10) XP(R) Rabbit mAb Cat#: 3925, PTMScan(R) Ubiquitin Branch Motif (K-e-GG) Immunoaffinity Beads Cat#: 1990
Curated Info

16

Guo A (2010) CST Curation Set: 10260; Year: 2010; Biosample/Treatment: cell line, L363/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: Ub(K-e-GG) Antibodies Used to Purify Peptides prior to LCMS: Ubiquitin (D4A7A10) XP(R) Rabbit mAb Cat#: 3925, PTMScan(R) Ubiquitin Branch Motif (K-e-GG) Immunoaffinity Beads Cat#: 1990
Curated Info

17

Guo A (2010) CST Curation Set: 10262; Year: 2010; Biosample/Treatment: cell line, RPMI-8266/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: Ub(K-e-GG) Antibodies Used to Purify Peptides prior to LCMS: Ubiquitin (D4A7A10) XP(R) Rabbit mAb Cat#: 3925, PTMScan(R) Ubiquitin Branch Motif (K-e-GG) Immunoaffinity Beads Cat#: 1990
Curated Info

18

Guo A (2010) CST Curation Set: 10263; Year: 2010; Biosample/Treatment: cell line, RPMI-8266/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: Ub(K-e-GG) Antibodies Used to Purify Peptides prior to LCMS: Ubiquitin (D4A7A10) XP(R) Rabbit mAb Cat#: 3925, PTMScan(R) Ubiquitin Branch Motif (K-e-GG) Immunoaffinity Beads Cat#: 1990
Curated Info

19

Possemato A (2010) CST Curation Set: 10258; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: Ub(K-e-GG) Antibodies Used to Purify Peptides prior to LCMS: Ubiquitin (D4A7A10) XP(R) Rabbit mAb Cat#: 3925, PTMScan(R) Ubiquitin Branch Motif (K-e-GG) Immunoaffinity Beads Cat#: 1990
Curated Info

20

Possemato A (2010) CST Curation Set: 9654; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: Ub(K-e-GG) Antibodies Used to Purify Peptides prior to LCMS: Ubiquitin (D4A7A10) XP(R) Rabbit mAb Cat#: 3925, PTMScan(R) Ubiquitin Branch Motif (K-e-GG) Immunoaffinity Beads Cat#: 1990
Curated Info

21

Beausoleil S (2010) CST Curation Set: 9659; Year: 2010; Biosample/Treatment: cell line, JJN3/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: Ub(K-e-GG) Antibodies Used to Purify Peptides prior to LCMS: Ubiquitin (D4A7A10) XP(R) Rabbit mAb Cat#: 3925, PTMScan(R) Ubiquitin Branch Motif (K-e-GG) Immunoaffinity Beads Cat#: 1990
Curated Info

22

Guo A (2010) CST Curation Set: 9183; Year: 2010; Biosample/Treatment: cell line, DND-41/untreated; Disease: acute lymphocytic leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: Ub(K-e-GG) Antibodies Used to Purify Peptides prior to LCMS: Ubiquitin (D4A7A10) XP(R) Rabbit mAb Cat#: 3925, PTMScan(R) Ubiquitin Branch Motif (K-e-GG) Immunoaffinity Beads Cat#: 1990
Curated Info

23

Guo A (2010) CST Curation Set: 9186; Year: 2010; Biosample/Treatment: cell line, Reh/untreated; Disease: acute lymphocytic leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: Ub(K-e-GG) Antibodies Used to Purify Peptides prior to LCMS: Ubiquitin (D4A7A10) XP(R) Rabbit mAb Cat#: 3925, PTMScan(R) Ubiquitin Branch Motif (K-e-GG) Immunoaffinity Beads Cat#: 1990
Curated Info

24

Guo A (2010) CST Curation Set: 9187; Year: 2010; Biosample/Treatment: cell line, SEM/untreated; Disease: acute lymphocytic leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: Ub(K-e-GG) Antibodies Used to Purify Peptides prior to LCMS: Ubiquitin (D4A7A10) XP(R) Rabbit mAb Cat#: 3925, PTMScan(R) Ubiquitin Branch Motif (K-e-GG) Immunoaffinity Beads Cat#: 1990
Curated Info

25

Guo A (2010) CST Curation Set: 9185; Year: 2010; Biosample/Treatment: cell line, K-562/untreated; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: Ub(K-e-GG) Antibodies Used to Purify Peptides prior to LCMS: Ubiquitin (D4A7A10) XP(R) Rabbit mAb Cat#: 3925, PTMScan(R) Ubiquitin Branch Motif (K-e-GG) Immunoaffinity Beads Cat#: 1990
Curated Info

26

Guo A (2010) CST Curation Set: 9184; Year: 2010; Biosample/Treatment: cell line, Jurkat/untreated; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: Ub(K-e-GG) Antibodies Used to Purify Peptides prior to LCMS: Ubiquitin (D4A7A10) XP(R) Rabbit mAb Cat#: 3925, PTMScan(R) Ubiquitin Branch Motif (K-e-GG) Immunoaffinity Beads Cat#: 1990
Curated Info

27

Zhou J (2010) CST Curation Set: 9131; Year: 2010; Biosample/Treatment: cell line, NCCIT/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: Ub(K-e-GG)
Curated Info

28

Zhou J (2010) CST Curation Set: 9132; Year: 2010; Biosample/Treatment: cell line, NTERA-2/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: Ub(K-e-GG)
Curated Info

29

Possemato A (2010) CST Curation Set: 9128; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: Ub(K-e-GG) Antibodies Used to Purify Peptides prior to LCMS: Ubiquitin (D4A7A10) XP(R) Rabbit mAb Cat#: 3925, PTMScan(R) Ubiquitin Branch Motif (K-e-GG) Immunoaffinity Beads Cat#: 1990
Curated Info

30

Moritz A (2010) CST Curation Set: 9063; Year: 2010; Biosample/Treatment: cell line, K-562/Peroxide; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: Ub(K-e-GG)
Curated Info

31

Moritz A (2010) CST Curation Set: 9062; Year: 2010; Biosample/Treatment: cell line, HeLa/untreated; Disease: cervical adenocarcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: Ub(K-e-GG)
Curated Info

32

Guo A (2009) CST Curation Set: 8684; Year: 2009; Biosample/Treatment: cell line, Karpas-620/Velcade; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: Ub(K-e-GG) Antibodies Used to Purify Peptides prior to LCMS: Ubiquitin (D4A7A10) XP(R) Rabbit mAb Cat#: 3925, PTMScan(R) Ubiquitin Branch Motif (K-e-GG) Immunoaffinity Beads Cat#: 1990
Curated Info

33

Guo A (2009) CST Curation Set: 8683; Year: 2009; Biosample/Treatment: cell line, Karpas-620/Velcade; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: Ub(K-e-GG) Antibodies Used to Purify Peptides prior to LCMS: Ubiquitin (D4A7A10) XP(R) Rabbit mAb Cat#: 3925, PTMScan(R) Ubiquitin Branch Motif (K-e-GG) Immunoaffinity Beads Cat#: 1990
Curated Info

34

Guo A (2009) CST Curation Set: 8668; Year: 2009; Biosample/Treatment: cell line, RPMI-8266/Velcade; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: Ub(K-e-GG) Antibodies Used to Purify Peptides prior to LCMS: Ubiquitin (D4A7A10) XP(R) Rabbit mAb Cat#: 3925, PTMScan(R) Ubiquitin Branch Motif (K-e-GG) Immunoaffinity Beads Cat#: 1990
Curated Info

35

Guo A (2009) CST Curation Set: 8669; Year: 2009; Biosample/Treatment: cell line, RPMI-8266/Velcade; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: Ub(K-e-GG) Antibodies Used to Purify Peptides prior to LCMS: Ubiquitin (D4A7A10) XP(R) Rabbit mAb Cat#: 3925, PTMScan(R) Ubiquitin Branch Motif (K-e-GG) Immunoaffinity Beads Cat#: 1990
Curated Info

36

Guo A (2009) CST Curation Set: 8667; Year: 2009; Biosample/Treatment: cell line, RPMI-8266/Velcade; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: Ub(K-e-GG) Antibodies Used to Purify Peptides prior to LCMS: Ubiquitin (D4A7A10) XP(R) Rabbit mAb Cat#: 3925, PTMScan(R) Ubiquitin Branch Motif (K-e-GG) Immunoaffinity Beads Cat#: 1990
Curated Info

37

Guo A (2009) CST Curation Set: 8663; Year: 2009; Biosample/Treatment: cell line, KMS-27/Velcade; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: Ub(K-e-GG) Antibodies Used to Purify Peptides prior to LCMS: Ubiquitin (D4A7A10) XP(R) Rabbit mAb Cat#: 3925, PTMScan(R) Ubiquitin Branch Motif (K-e-GG) Immunoaffinity Beads Cat#: 1990
Curated Info

38

Guo A (2009) CST Curation Set: 8657; Year: 2009; Biosample/Treatment: cell line, KMS-12-BM/Velcade; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: Ub(K-e-GG) Antibodies Used to Purify Peptides prior to LCMS: Ubiquitin (D4A7A10) XP(R) Rabbit mAb Cat#: 3925, PTMScan(R) Ubiquitin Branch Motif (K-e-GG) Immunoaffinity Beads Cat#: 1990
Curated Info

39

Guo A (2009) CST Curation Set: 8656; Year: 2009; Biosample/Treatment: cell line, KMS-12-BM/Velcade; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: Ub(K-e-GG) Antibodies Used to Purify Peptides prior to LCMS: Ubiquitin (D4A7A10) XP(R) Rabbit mAb Cat#: 3925, PTMScan(R) Ubiquitin Branch Motif (K-e-GG) Immunoaffinity Beads Cat#: 1990
Curated Info

40

Guo A (2009) CST Curation Set: 8654; Year: 2009; Biosample/Treatment: cell line, KMS-12-BM/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: Ub(K-e-GG) Antibodies Used to Purify Peptides prior to LCMS: Ubiquitin (D4A7A10) XP(R) Rabbit mAb Cat#: 3925, PTMScan(R) Ubiquitin Branch Motif (K-e-GG) Immunoaffinity Beads Cat#: 1990
Curated Info

41

Guo A (2009) CST Curation Set: 8658; Year: 2009; Biosample/Treatment: cell line, KMS-12-BM/Velcade; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: Ub(K-e-GG) Antibodies Used to Purify Peptides prior to LCMS: Ubiquitin (D4A7A10) XP(R) Rabbit mAb Cat#: 3925, PTMScan(R) Ubiquitin Branch Motif (K-e-GG) Immunoaffinity Beads Cat#: 1990
Curated Info

42

Guo A (2009) CST Curation Set: 8666; Year: 2009; Biosample/Treatment: cell line, RPMI-8266/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: Ub(K-e-GG) Antibodies Used to Purify Peptides prior to LCMS: Ubiquitin (D4A7A10) XP(R) Rabbit mAb Cat#: 3925, PTMScan(R) Ubiquitin Branch Motif (K-e-GG) Immunoaffinity Beads Cat#: 1990
Curated Info

43

Guo A (2009) CST Curation Set: 8660; Year: 2009; Biosample/Treatment: cell line, KMS-27/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: Ub(K-e-GG) Antibodies Used to Purify Peptides prior to LCMS: Ubiquitin (D4A7A10) XP(R) Rabbit mAb Cat#: 3925, PTMScan(R) Ubiquitin Branch Motif (K-e-GG) Immunoaffinity Beads Cat#: 1990
Curated Info

44

Guo A (2009) CST Curation Set: 8647; Year: 2009; Biosample/Treatment: cell line, JJN3/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: Ub(K-e-GG) Antibodies Used to Purify Peptides prior to LCMS: Ubiquitin (D4A7A10) XP(R) Rabbit mAb Cat#: 3925, PTMScan(R) Ubiquitin Branch Motif (K-e-GG) Immunoaffinity Beads Cat#: 1990
Curated Info

45

Guo A (2009) CST Curation Set: 8650; Year: 2009; Biosample/Treatment: cell line, JJN3/Velcade; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: Ub(K-e-GG) Antibodies Used to Purify Peptides prior to LCMS: Ubiquitin (D4A7A10) XP(R) Rabbit mAb Cat#: 3925, PTMScan(R) Ubiquitin Branch Motif (K-e-GG) Immunoaffinity Beads Cat#: 1990
Curated Info

46

Guo A (2009) CST Curation Set: 8649; Year: 2009; Biosample/Treatment: cell line, JJN3/Velcade; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: Ub(K-e-GG) Antibodies Used to Purify Peptides prior to LCMS: Ubiquitin (D4A7A10) XP(R) Rabbit mAb Cat#: 3925, PTMScan(R) Ubiquitin Branch Motif (K-e-GG) Immunoaffinity Beads Cat#: 1990
Curated Info

47

Guo A (2009) CST Curation Set: 8642; Year: 2009; Biosample/Treatment: cell line, U266/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: Ub(K-e-GG) Antibodies Used to Purify Peptides prior to LCMS: Ubiquitin (D4A7A10) XP(R) Rabbit mAb Cat#: 3925, PTMScan(R) Ubiquitin Branch Motif (K-e-GG) Immunoaffinity Beads Cat#: 1990
Curated Info

48

Guo A (2009) CST Curation Set: 8652; Year: 2009; Biosample/Treatment: cell line, JJN3/Velcade; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: Ub(K-e-GG) Antibodies Used to Purify Peptides prior to LCMS: Ubiquitin (D4A7A10) XP(R) Rabbit mAb Cat#: 3925, PTMScan(R) Ubiquitin Branch Motif (K-e-GG) Immunoaffinity Beads Cat#: 1990
Curated Info

49

Guo A (2009) CST Curation Set: 8641; Year: 2009; Biosample/Treatment: cell line, U266/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: Ub(K-e-GG) Antibodies Used to Purify Peptides prior to LCMS: Ubiquitin (D4A7A10) XP(R) Rabbit mAb Cat#: 3925, PTMScan(R) Ubiquitin Branch Motif (K-e-GG) Immunoaffinity Beads Cat#: 1990
Curated Info

50

Guo A (2009) CST Curation Set: 8644; Year: 2009; Biosample/Treatment: cell line, U266/Velcade; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: Ub(K-e-GG) Antibodies Used to Purify Peptides prior to LCMS: Ubiquitin (D4A7A10) XP(R) Rabbit mAb Cat#: 3925, PTMScan(R) Ubiquitin Branch Motif (K-e-GG) Immunoaffinity Beads Cat#: 1990
Curated Info

51

Guo A (2009) CST Curation Set: 8639; Year: 2009; Biosample/Treatment: cell line, L363/Velcade; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: Ub(K-e-GG) Antibodies Used to Purify Peptides prior to LCMS: Ubiquitin (D4A7A10) XP(R) Rabbit mAb Cat#: 3925, PTMScan(R) Ubiquitin Branch Motif (K-e-GG) Immunoaffinity Beads Cat#: 1990
Curated Info

52

Guo A (2009) CST Curation Set: 8637; Year: 2009; Biosample/Treatment: cell line, L363/Velcade; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: Ub(K-e-GG) Antibodies Used to Purify Peptides prior to LCMS: Ubiquitin (D4A7A10) XP(R) Rabbit mAb Cat#: 3925, PTMScan(R) Ubiquitin Branch Motif (K-e-GG) Immunoaffinity Beads Cat#: 1990
Curated Info

53

Guo A (2009) CST Curation Set: 8640; Year: 2009; Biosample/Treatment: cell line, L363/Velcade; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: Ub(K-e-GG) Antibodies Used to Purify Peptides prior to LCMS: Ubiquitin (D4A7A10) XP(R) Rabbit mAb Cat#: 3925, PTMScan(R) Ubiquitin Branch Motif (K-e-GG) Immunoaffinity Beads Cat#: 1990
Curated Info

54

Guo A (2009) CST Curation Set: 8638; Year: 2009; Biosample/Treatment: cell line, L363/Velcade; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: Ub(K-e-GG) Antibodies Used to Purify Peptides prior to LCMS: Ubiquitin (D4A7A10) XP(R) Rabbit mAb Cat#: 3925, PTMScan(R) Ubiquitin Branch Motif (K-e-GG) Immunoaffinity Beads Cat#: 1990
Curated Info

55

Guo A (2009) CST Curation Set: 8636; Year: 2009; Biosample/Treatment: cell line, L363/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: Ub(K-e-GG) Antibodies Used to Purify Peptides prior to LCMS: Ubiquitin (D4A7A10) XP(R) Rabbit mAb Cat#: 3925, PTMScan(R) Ubiquitin Branch Motif (K-e-GG) Immunoaffinity Beads Cat#: 1990
Curated Info

56

Guo A (2009) CST Curation Set: 8630; Year: 2009; Biosample/Treatment: cell line, AMO-1/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: Ub(K-e-GG) Antibodies Used to Purify Peptides prior to LCMS: Ubiquitin (D4A7A10) XP(R) Rabbit mAb Cat#: 3925, PTMScan(R) Ubiquitin Branch Motif (K-e-GG) Immunoaffinity Beads Cat#: 1990
Curated Info

57

Possemato A (2009) CST Curation Set: 8587; Year: 2010; Biosample/Treatment: cell line, PC3/Velcade; Disease: prostate cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: Ub(K-e-GG)
Curated Info

58

Possemato A (2009) CST Curation Set: 8585; Year: 2010; Biosample/Treatment: cell line, PC3/Geldanamycin; Disease: prostate cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: Ub(K-e-GG)
Curated Info

59

Possemato A (2009) CST Curation Set: 8586; Year: 2010; Biosample/Treatment: cell line, PC3/Velcade; Disease: prostate cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: Ub(K-e-GG)
Curated Info

60

Possemato A (2009) CST Curation Set: 8581; Year: 2010; Biosample/Treatment: cell line, PC3/control; Disease: prostate cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: Ub(K-e-GG)
Curated Info

61

Possemato A (2009) CST Curation Set: 8584; Year: 2010; Biosample/Treatment: cell line, PC3/Geldanamycin; Disease: prostate cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: Ub(K-e-GG)
Curated Info

62

Zhi G, et al. (2009) Fanconi anemia complementation group FANCD2 protein serine 331 phosphorylation is important for fanconi anemia pathway function and BRCA2 interaction. Cancer Res 69, 8775-83
19861535   Curated Info

63

Possemato A (2009) CST Curation Set: 8247; Year: 2010; Biosample/Treatment: cell line, LNCaP/Velcade; Disease: prostate cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: Ub(K-e-GG)
Curated Info

64

Possemato A (2009) CST Curation Set: 8246; Year: 2010; Biosample/Treatment: cell line, LNCaP/Velcade; Disease: prostate cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: Ub(K-e-GG)
Curated Info

65

Montes de Oca R, et al. (2005) Regulated interaction of the Fanconi anemia protein, FANCD2, with chromatin. Blood 105, 1003-9
15454491   Curated Info

66

Taniguchi T, et al. (2002) S-phase-specific interaction of the Fanconi anemia protein, FANCD2, with BRCA1 and RAD51. Blood 100, 2414-20
12239151   Curated Info

67

Taniguchi T, D'Andrea AD (2002) The Fanconi anemia protein, FANCE, promotes the nuclear accumulation of FANCC. Blood 100, 2457-62
12239156   Curated Info

68

Garcia-Higuera I, et al. (2001) Interaction of the Fanconi anemia proteins and BRCA1 in a common pathway. Mol Cell 7, 249-62
11239454   Curated Info